A normally benign protein found in the human body appears to be able – when paired with nanoparticles – to zero in on and kill certain cancer cells, without having to also load those particles with chemothera...
A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University o...
Research and Markets (http://www.researchandmarkets.com/research/68aa8e/design_of_heteroge) has announced the addition of John Wiley and Sons Ltd's new book "Design of Heterogeneous Catalysts: New Approaches bas...
Another reason for including asthma on the list of potential health risks posed by secondhand tobacco smoke, especially for non-smokers, has been uncovered. Furthermore, the practice of using ozone to remove the smell of tobacco smoke from indoor environments, including hotel rooms and the interiors of vehicles, is probably a bad idea.
The University of Texas – Pan American (UTPA) has launched a start-up company that may revolutionize manufacturing.
FibeRio Technology Corporation is perfecting a new technology called ForceSpinning ™ to c...
Extra-hard coatings made from diamond-like carbon (DLC) extend the operating lifetime of tools and components. In artificial joints, however, these coatings often fail because they detach. Empa researchers found out why – and developed methods to both make the interface between the DLC layer and the metal underneath corrosion-resistant and to predict the lifetime of the implants.
In experiments with potentially broad health care implications, a research team led by a University of Washington physicist has devised a method that works at a very small scale to sequence DNA quickly and relatively ine...
Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH).
In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision. The team developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls. The study, published online in advance of print in Molecular Therapy, brings researchers closer to a non-viral gene therapy treatment for degenerative eye disorders.
Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.